Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.60
-0.41 (-1.58%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 138.27 | 172.92 | 114.09 | 49.3 | 87.7 | 10.61 |
Short-Term Investments | 523.14 | 483.71 | 84.1 | 187.26 | 22.41 | - |
Cash & Short-Term Investments | 661.41 | 656.64 | 198.19 | 236.57 | 110.11 | 10.61 |
Cash Growth | 103.56% | 231.32% | -16.22% | 114.85% | 937.60% | 653.16% |
Prepaid Expenses | 4.39 | 4.75 | 7.16 | 12.54 | 2.7 | 0.46 |
Restricted Cash | - | - | - | - | - | 0.05 |
Total Current Assets | 665.8 | 661.39 | 205.35 | 249.1 | 112.81 | 11.12 |
Property, Plant & Equipment | 0.03 | 0.04 | 0.05 | - | - | - |
Long-Term Investments | - | - | - | 2.48 | - | - |
Long-Term Deferred Charges | 0.2 | 0.2 | 0.4 | - | 1.6 | 0 |
Other Long-Term Assets | 1.82 | 0.18 | 0.1 | 0.05 | 0.03 | - |
Total Assets | 667.85 | 661.81 | 205.9 | 251.64 | 114.44 | 11.13 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.07 | 2.02 | 0.48 | 0.6 | 1.91 | 0.76 |
Accrued Expenses | 18.25 | 13.1 | 14.17 | 9.88 | 6.16 | 4.29 |
Total Current Liabilities | 19.32 | 15.11 | 14.65 | 10.48 | 8.07 | 5.05 |
Total Liabilities | 116.94 | 15.11 | 14.65 | 10.48 | 8.07 | 5.05 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-In Capital | 1,288 | 1,104 | 493.77 | 365.86 | 0.54 | 0.09 |
Retained Earnings | -737.58 | -457.17 | -302.52 | -124.71 | -52.81 | -23.01 |
Total Common Equity | 550.92 | 646.69 | 191.26 | 241.15 | -52.27 | -22.93 |
Shareholders' Equity | 550.92 | 646.69 | 191.26 | 241.15 | 106.38 | 6.07 |
Total Liabilities & Equity | 667.85 | 661.81 | 205.9 | 251.64 | 114.44 | 11.13 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 97.62 | - | - | - | - | - |
Net Cash (Debt) | 563.8 | 656.64 | 198.19 | 236.57 | 110.11 | 10.61 |
Net Cash Growth | 73.52% | 231.32% | -16.22% | 114.85% | 937.60% | - |
Net Cash Per Share | 7.06 | 9.71 | 4.08 | 6.54 | 21.31 | 2.13 |
Filing Date Shares Outstanding | 88.41 | 82.4 | 49.84 | 49.63 | 40.86 | 5.44 |
Total Common Shares Outstanding | 88.35 | 81.54 | 49.82 | 41.13 | 6.42 | 5.44 |
Working Capital | 646.48 | 646.27 | 190.71 | 238.62 | 104.74 | 6.07 |
Book Value Per Share | 6.24 | 7.93 | 3.84 | 5.86 | -8.14 | -4.21 |
Tangible Book Value | 550.92 | 646.69 | 191.26 | 241.15 | -52.27 | -22.93 |
Tangible Book Value Per Share | 6.24 | 7.93 | 3.84 | 5.86 | -8.14 | -4.21 |